Literature DB >> 15661413

Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy.

Michael Froehner1, Rainer Koch, Rainer J Litz, Sven Oehlschlaeger, Oliver W Hakenberg, Manfred P Wirth.   

Abstract

OBJECTIVE: To compare different comorbidity classifications as predictors of survival after radical prostatectomy (RPE).
METHODS: 444 consecutive RPE patients (mean follow-up 6.9 years) were stratified according to age, Charlson score, American Society of Anesthesiologists Physical Status classification (ASA), New York Heart Association classification of cardiac insufficiency, classification of angina pectoris of the Canadian Cardiovascular Society and a combination of both cardiac risk scores. Comorbid and overall mortality were the study endpoints. Mantel-Haenszel hazard ratios, p values and 8-year survival probabilities were used for comparison. A modified Charlson score was created by a restriction to the five individual conditions significantly associated with comorbid mortality.
RESULTS: When three strata (low, intermediate, high risk) were used, all stratifications displayed dose-response patterns and reached statistical significance as predictors of survival at least for the high-risk group. Only the ASA classification, however, discriminated three significantly different risk groups. Only the modified (restricted) Charlson score reached statistical significance as predictor of comorbid mortality in the age group of 70 or more years.
CONCLUSION: Although all investigated comorbidity classifications had some prognostic relevance in patients selected for RPE, their clinical applicability appears to be limited beyond the 70th year of life. The results of this study might, nevertheless, assist the treatment decision in patients with low-risk tumors eligible for modern watchful waiting strategies who mainly belong to the age group between 60-69 years where comorbidity seems to be of distinct prognostic value.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661413     DOI: 10.1016/j.eururo.2004.07.031

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  5 in total

1.  [Research in urologic university clinics. Assessment of current status and perspectives].

Authors:  K Miller; H Krause
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  Prediction of mortality after radical prostatectomy by Charlson comorbidity index.

Authors:  Thomas J Guzzo; Paul Dluzniewski; Ryan Orosco; Elizabeth A Platz; Alan W Partin; Misop Han
Journal:  Urology       Date:  2010-09       Impact factor: 2.649

3.  Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy.

Authors:  Costanza Chiumento; Alba Fiorentino; Mariella Cozzolino; Rocchina Caivano; Stefania Clemente; Piernicola Pedicini; Vincenzo Fusco
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

4.  Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer.

Authors:  Ming Yin; Jing Zhao; Paul Monk; Douglas Martin; Edmund Folefac; Monika Joshi; Ning Jin; Amir Mortazavi; Claire Verschraegen; Steven Clinton
Journal:  Cancer Med       Date:  2019-11-07       Impact factor: 4.452

5.  Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy.

Authors:  Joo Yong Lee; Dae Hun Lee; Nam Hoon Cho; Koon Ho Rha; Young Deuk Choi; Sung Joon Hong; Seung Choul Yang; Kang Su Cho
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.